Patents by Inventor Karsten Lundgren

Karsten Lundgren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods relating to the degradation of Cdc25A in response to DNA damage
    Publication number: 20020147145
    Abstract: Cdc25A has a role in a further signalling pathway for DNA repair which operates in response to DNA damage, in which Chk1 or Chk2 are activated following DNA damage and phosphorylate Cdc25A at one or more serine residues, and more particularly at Ser123 and/or Ser262 and/or Ser292 and/or Ser504. The phosphorylated Cdc25A is then recognized by the F-box protein and is then degraded in a proteasome dependent manner, thereby allowing the cells to undergo cell cycle arrest and repair. Accordingly, by interfering with the phosphorylation and/or degradation of Cdc25A and/or using other strategies to maintain Cdc25A level, this pathway can be used to prevent cells from undergoing repair and thereby increasing the accumulation of DNA damage in the cells, e.g. increasing the fraction of tumor cells which can be killed by DNA damaging therapeutic agents, such as radiation or anti-tumor drugs, or which undergo apoptosis.
    Type: Application
    Filed: September 7, 2001
    Publication date: October 10, 2002
    Applicant: Zealand Pharmaceuticals A/S
    Inventors: Niels Mailand, Jacob Falck Hansen, Jiri Bartek, Jiri Lukas, Claudia Lukas, Randi Syljuasen, Karsten Lundgren
  • Method of inhibiting liver glycogen phosphorylase with 2-alkylpyrrolidines
    Patent number: 6451836
    Abstract: The present invention relates to (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines and their use for inhibiting liver glycogen phosphorylase.
    Type: Grant
    Filed: August 24, 1998
    Date of Patent: September 17, 2002
    Assignee: Novo Nordisk A/S
    Inventors: Karsten Lundgren, Palle Jakobsen, Marit Kristiansen, Leif Nørskov-Lauritsen, Lars Naerum
  • Heterocyclic compounds
    Patent number: 6046214
    Abstract: Novel piperidine compounds are provided, and those compounds are useful in the treatment and/or prevention of diabetes, and especially non-insulin dependent diabetes (NIDDM or type 2 diabetes) including overnight or meal treatment and treatment or prevention of longterm complications, such as retinopathy, neuropathy, nephropathy, and micro- and macroangiopathy; treatment of hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis or myocardial ischemia.
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: April 4, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Marit Kristiansen, Palle Jakobsen, Jane Marie Lundbeck, Birgitte S.o slashed.kilde, Karsten Lundgren
  • Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
    Patent number: 5863903
    Abstract: The present invention relates to hydroxy alkyl piperidine compounds and pharmaceutical compositions thereof which can be used to treat diabetes.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: January 26, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Karsten Lundgren, Ole Kirk
  • 2-alkylpyrrolidines
    Patent number: 5854272
    Abstract: The present invention relates to (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines and their use for the treatment of diabetes.
    Type: Grant
    Filed: July 14, 1997
    Date of Patent: December 29, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Karsten Lundgren, Palle Jakobsen, Marit Kristiansen, Leif N.o slashed.rskov-Lauritsen, Lars Naerum